Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574481 · ClinicalTrials.gov registry record · NA
ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 524
- Enrollment target
NCT02574481 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 524 participants.
The verdict
NCT02574481, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 524 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length. Long Lesion Substudy: to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions \>140 mm and ≤ 190 mm in length.
Interventions
- DEVICE ELUVIA (Stent Implantation)
- DEVICE Zilver PTX (Stent Implantation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2015-12 |
| Est. Completion | 2022-04-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02574481
The ClinicalTrials.gov registry entry for NCT02574481 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 524 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ELUVIA (Stent Implantation) is the first listed.
NCT02574481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02574481 about?
NCT02574481 is a clinical study titled "ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent". The primary objective of this trial is to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length. Lo...
What is the current status of trial NCT02574481?
This trial is currently completed. It is a NA study. The enrollment target is 524 participants. The study started on 2015-12. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT02574481?
The interventions under investigation include: ELUVIA (Stent Implantation) (DEVICE), Zilver PTX (Stent Implantation) (DEVICE).
Who is sponsoring clinical trial NCT02574481?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.